AOD-9604 in Izumo — Fat Loss Peptide Research Guide
AOD-9604 research guide for Izumo. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
For anyone in Izumo looking to source AOD-9604, the first thing to know is that this compound is available only through an online research supply market. The benefit of this online-only market is that serious vendors compete aggressively on their analytical documentation, giving researchers access to better quality signals than any local market ever offers. The primary quality indicators for AOD-9604 are HPLC purity ≥98%, molecular identity established via mass spectrometry, and a bacterial endotoxin panel — all documented in a lot-traced Certificate of Analysis. This guide takes Izumo researchers through that evaluation process and explains the signals that distinguish quality AOD-9604 suppliers.
AOD-9604 Mechanisms Explained
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: AOD-9604 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Izumo comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Sourcing Research-Grade AOD-9604
The first step for any Izumo researcher sourcing AOD-9604 is identifying 2-3 vendors with documented positive community reputations — commercial rankings reflect SEO budgets rather than product quality. When reviewing a AOD-9604 COA, verify: the batch number corresponds to your vial, HPLC purity is ≥98%, mass spec confirms the correct peptide, and endotoxin levels are within acceptable research limits. Warning signs in AOD-9604 vendor evaluation: prices significantly below market average, unclear production details, no community presence, and COAs that omit endotoxin testing. Keep lyophilised AOD-9604 at minus 20 degrees Celsius until ready to use; reconstitute only the quantity required for your immediate research and return unused portion to the freezer.
Order AOD-9604 — ships to Izumo
COA-verified · International tracking · Research grade
All use of AOD-9604 in Izumo or anywhere must be research use only — this compound is not approved for therapeutic human application, and all handling should follow research laboratory protocols. Temperature excursions — even brief warming above recommended storage temperature — can partially degrade AOD-9604 without detectable changes to appearance; always verify cold chain was maintained during shipping. Endotoxin testing in the AOD-9604 COA is absolutely required — gram-negative bacterial endotoxins can trigger serious inflammatory reactions at trace quantities, and no discount compensates for this missing data. Researchers running multi-compound protocols with AOD-9604 should review the available literature for documented interactions before beginning combination research.
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
